Biodefense PPT
                     Biodefense Market
 
Biodefense Market to 
2027 - Global Analysis 
and Forecasts by 
Product (Anthrax, Small 
Pox, Botulism, 
Radiation/Nuclear, and 
Others) and Geography
Hemophilia Treatment Market 
Current and future Market Scenario
 According to The Insight Partners market research study of ‘Biodefense Market to 2027 – Global Analysis 
and Forecasts by Product.’ The global Biodefense market is expected to reach US$ 8,350.74 Mn in 2027 
from US$ 4,108.24 Mn in 2019. The market is estimated to grow with a CAGR of 9.4% from 2020-2027. 
  The report provides trends prevailing in the global biodefense market and the factors driving market along 
with those that act as hindrances.
 The global biodefense market on the basis of product is segmented into anthrax, small pox, botulism, 
nuclear/radiation and others. In 2019, the anthrax segment accounted for the largest market share in the 
global biodefense market.
 The segment is expected to continue its dominance over the forecast period owing to increasing funding by 
the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly 
through a variety of initiatives, such as BioShield Act, Biomedical Advanced Research and Development 
Authority (BARDA), and the Joint Program Executive Office for Chemical & Biological Defense. For instance, 
the US Department of Health and Human Services announced it would purchase an anthrax treatment for 
$25. Million from Elusys Therapeutics Inc., as a part of an emergency preparedness plan, in 2018.
Key Findings
 
 The growth of the market is attributed to the some key driving factors such as presence of favorable 
government initiatives increase in the number of naturally occurring outbreaks, increasing threat of 
biological weapons and nuclear armed ICBM. However, low R&D funding by government in developing and 
underdeveloped economies are expected to restraint the growth of the market during the forecast years.
Market Insights
Presence of favorable government initiatives
Every year, the government is spending heavily on the R&D of vaccines to stay prepared for any bioterrorism 
attacks. For instance, in 2018, the US government released the National Biodefense Strategy and 
Implementation Plan, the National Security Strategy, the National Defense Strategy, and the National 
Counterterrorism Strategy, and the National Counter WMD Strategy, all of which include biosecurity and 
biodefense. In addition, the US government is also preparing for Global Health Security Strategy and 
supporting the development of a 2024 framework of the Global Health Security Agenda, which involves 
prevention, detection, and response to natural, accidental, and intentional biological threats.
Hemophilia Treatment Market 
 
Market Segments
Global Biodefense Market – By Product  
Anthrax
Small Pox
Botulism
Radiation/Nuclear
Others
Hemophilia Treatment Market 
Dominating Segments
 
 The biodefense market, by product, is segmented into anthrax, small pox, botulism, radiation/nuclear and 
  others. In 2019, the anthrax segment accounted for the largest market share in the global biodefense 
market. The segment is expected to continue its dominance over the forecast period owing to increasing 
funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax 
mainly through a variety of initiatives, such as BioShield Act, Biomedical Advanced Research and 
Development Authority (BARDA), and the Joint Program Executive Office for Chemical & Biological Defense.
 Strategic Insights
 Product launches, and approvals strategy is commonly adopted by companies to expand their footprint 
worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in 
order to expand its product portfolio.
 The market players operating in the biodefense market adopt the strategy of expansion to enlarge customer 
base across the world, which also permits the players to maintain their brand name globally. For instance, in 
January 2017, Emergent BioSolutions Inc. has received the German Federal Ministry of Health Approval to 
market BioThrax (Anthrax Vaccine Adsorbed) manufactured in Building 55 in Germany.
  
Dominating Segments
 Download PDF Brochure https://www.theinsightpartners.com/sample/TIPRE00005377/
Dominating Segments
 Biodefense Market – By Geography
 North America
 US
 Canada
 Mexico
 Europe
 France
 Germany
 Italy
 UK
 Spain
 Rest of Europe
Dominating Segments
 Asia Pacific
 China
 India
 South Korea
 Japan
 Australia
 Rest of Asia Pacific
Dominating Segments
 Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
 Rest of Middle East and Africa
 South America
 Brazil
 Argentina
 Rest of South America
Hemophilia Treatment Market  
Leading Players
 Company Profiles
Bavarian Nordic
Alnylam Pharmaceuticals, Inc.
SIGA Technologies
Emergent BioSolutions Inc.
Cleveland Bio Labs
Dynavax Technologies
Elusys Therapeutics, Inc.
Soligenix
Altimmune
Pluristem Therapeutics
  REGIONAL FRAMEWORK
REGIONAL FRAMEWORK
  Hemophilia Treatment Market  
 
 
 Hemophilia Treatment Market 
 
 
        
Access Full Research Report at: 
https://www.theinsightpartners.com/reports/biodefence-market
Thank You! 
 Thank You!